Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients
Article first published online: 28 JUN 2008
Journal of Gastroenterology and Hepatology
Volume 5, Issue 6, pages 616–626, December 1990
How to Cite
EBARA, M., OHTO, M., SUGIURA, N., KITA, K., YOSHIKAWA, M., OKUDA, K., KONDO, F. and KONDO, Y. (1990), Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. Journal of Gastroenterology and Hepatology, 5: 616–626. doi: 10.1111/j.1440-1746.1990.tb01115.x
- Issue published online: 28 JUN 2008
- Article first published online: 28 JUN 2008
- Accepted for publication 30 May 1990.
- hepatocellular carcinoma (HCC);
- interventional ultrasound;
- percutaneous ethanol injection (PEI)
Abstract Percutaneous ethanol injection (PEI) was applied to 120 lesions in 95 patients with hepatocellular carcinomas (HCC) smaller than 3 cm in the past 6 years. All main target tumours, in 67 patients who had been followed by sonography for more than 6 months after PEI, decreased in size; 28 tumours (41.8%) became undetectable and have remained so until now. The 1-, 2-, 3-, 4- and 5-year survival rates calculated by the Kaplan-Meier method were 93%, 81%, 65%, 52% and 28% respectively. These survival rates were better than those of patients with HCC smaller than 3 cm who did not receive anticancer treatment (P <0.01). The survival of patients of the Child's A or Child's B status was better than that of those with Child's C disease. Recurrence occurred in areas within the liver different from the original lesion in 34% in one year, 61% in two years and 66% in three years after PEI. PEI was then repeated in 61% of such patients.